We have taken advantage of the liposome active targeted technology in improving drug safety and efficacy to conquer the difficulties with liposomes in particle size distribution, drug loading, entrapped efficiency, stability, etc., and have obtained 14 Chinese patents for invention, 1 U.S. patent, 2 Japanese patents, 1 Australian patent, and PCT patents covering the U.S., Europe, Japan, South Korea, Canada and Australia, forming a complete independent intellectual property system and successfully establishing an active targeted nanopharmaceuticals delivery technology platform.